Serum contents of endocannabinoids are correlated with blood pressure in depressed women
Open Access
- 28 February 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Lipids in Health and Disease
- Vol. 11 (1), 32
- https://doi.org/10.1186/1476-511x-11-32
Abstract
Depression is known to be a risk factor for cardiovascular diseases but the underlying mechanisms remain unclear. Since recent preclinical evidence suggests that endogenous agonists of cannabinoid receptors (endocannabinoids) are involved in both cardiovascular function and depression, we asked whether endocannabinoids correlated with either in humans. Resting blood pressure and serum content of endocannabinoids in ambulatory, medication-free, female volunteers with depression (n = 28) and their age- and ethnicity-matched controls (n = 27) were measured. In females with depression, both diastolic and mean arterial blood pressures were positively correlated with serum contents of the endocannabinoids, N-arachidonylethanolamine (anandamide) and 2-arachidonoylglycerol. There was no correlation between blood pressure and endocannabinoids in control subjects. Furthermore, depressed women had significantly higher systolic blood pressure than control subjects. A larger body mass index was also found in depressed women, however, it was not significantly correlated with serum endocannabinoid contents. This preliminary study raises the possibility that endocannabinoids play a role in blood pressure regulation in depressives with higher blood pressure, and suggests an interrelationship among endocannabinoids, depression and cardiovascular risk factors in women.Keywords
This publication has 46 references indexed in Scilit:
- Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stressPsychoneuroendocrinology, 2009
- Serum Endocannabinoid Content is Altered in Females with Depressive Disorders: A Preliminary ReportPharmacopsychiatry, 2008
- Cannabinoid receptors in acute and chronic complications of atherosclerosisBritish Journal of Pharmacology, 2008
- Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?Behavioural Pharmacology, 2005
- Downregulation of Endocannabinoid Signaling in the Hippocampus Following Chronic Unpredictable StressNeuropsychopharmacology, 2004
- The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout miceLife Sciences, 2004
- Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in HypertensionCirculation, 2004
- Activation of PAF receptors results in enhanced synthesis of 2‐arachidonoylglycerol (2‐AG) in immune cellsThe FASEB Journal, 2001
- Cardiovascular Effects of 2-Arachidonoyl Glycerol in Anesthetized MiceHypertension, 2000
- An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial)American Heart Journal, 1999